Wells Fargo analyst Larry Biegelsen downgraded RxSight to Equal Weight from Overweight with a price target of $14, down from $20.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RXST:
- Needham healthcare analyst to hold an analyst/industry conference call
- RxSight raises FY22 revenue view to $47M-$48M from prior $44M-$46M
- RxSight reports Q3 EPS (61c), consensus (71c)
- RxSight, Inc. to Report Third Quarter 2022 Financial Results on November 7, 2022
Questions or Comments about the article? Write to editor@tipranks.com